等级
pharmaceutical primary standard
API类
piretanide
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
[S](=O)(=O)(N)c1c(c(cc(c1)C(=O)O)N3CCCC3)Oc2ccccc2
InChI
1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)
InChI key
UJEWTUDSLQGTOA-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Piretanide for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Effect of Na/K/2Cl transporter inhibition with piretanide on postischemic kidney function.
D Abendroth et al.
Transplantation proceedings, 28(1), 83-84 (1996-02-01)
H M Cox et al.
British journal of pharmacology, 113(4), 1243-1248 (1994-12-01)
1. The secretory responses to calcitonin gene-related peptide (CGRP) receptor agonists have been characterized in two human adenocarcinoma cell lines, namely HCA-7 and Colony-29 (Col-29) epithelia. These cells form polarized epithelial layers when grown on permeable supports and allow changes
R Genthon et al.
Therapie, 50(1), 47-51 (1995-01-01)
Thirty healthy volunteers received piretanide SR 6 mg/day (n = 15) or placebo (n = 15) in a 10-day double-blind parallel-group comparative trial. 24-h urine output was significantly greater with piretanide than with placebo on D1 (1919 +/- 434 ml
L Thijs et al.
Journal of cardiovascular pharmacology, 26(1), 33-38 (1995-07-01)
In a double-blind, randomized, multicenter trial, we compared the efficacy and safety of the fixed combination of 5 mg ramipril and 6 mg piretanide and the respective component monotherapies in hypertensive patients [supine diastolic blood pressure (DBP) 100-114 mm Hg].
[Study report: Hypertension therapy with organ protection. Piretanid and Ramipril: advantages with fixed combination].
Fortschritte der Medizin. Supplement : die Kongressinformation fur die Praxis, 164, 3-15 (1994-01-01)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门